ACADIA Pharmaceuticals/$ACAD
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Ticker
$ACAD
Sector
Primary listing
Employees
797
Headquarters
Website
ACAD Metrics
BasicAdvanced
$3.7B
9.55
$2.30
0.81
-
Price and volume
Market cap
$3.7B
Beta
0.81
52-week high
$28.35
52-week low
$13.40
Average daily volume
1.7M
Financial strength
Current ratio
3.833
Quick ratio
3.493
Long term debt to equity
3.304
Total debt to equity
3.304
Profitability
EBITDA (TTM)
116.592
Gross margin (TTM)
61.01%
Net profit margin (TTM)
36.49%
Operating margin (TTM)
9.78%
Effective tax rate (TTM)
-181.49%
Revenue per employee (TTM)
$1,340,000
Management effectiveness
Return on assets (TTM)
4.76%
Return on equity (TTM)
39.89%
Valuation
Price to earnings (TTM)
9.552
Price to revenue (TTM)
3.452
Price to book
3.03
Price to tangible book (TTM)
3.35
Price to free cash flow (TTM)
35.178
Free cash flow yield (TTM)
2.84%
Free cash flow per share (TTM)
0.625
Growth
Revenue change (TTM)
11.87%
Earnings per share change (TTM)
69.12%
3-year revenue growth (CAGR)
27.48%
10-year revenue growth (CAGR)
165.75%
3-year earnings per share growth (CAGR)
19.73%
10-year earnings per share growth (CAGR)
3.48%
What the Analysts think about ACAD
Analyst ratings (Buy, Hold, Sell) for ACADIA Pharmaceuticals stock.
ACAD Financial Performance
Revenues and expenses
ACAD Earnings Performance
Company profitability
ACAD News
AllArticlesVideos
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
Business Wire·2 weeks ago
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
Business Wire·1 month ago
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals (ACAD) has a market cap of $3.7B as of March 12, 2026.
What is the P/E ratio for ACADIA Pharmaceuticals stock?
The price to earnings (P/E) ratio for ACADIA Pharmaceuticals (ACAD) stock is 9.55 as of March 12, 2026.
Does ACADIA Pharmaceuticals stock pay dividends?
No, ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders as of March 12, 2026.
When is the next ACADIA Pharmaceuticals dividend payment date?
ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders.
What is the beta indicator for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals (ACAD) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.